The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hammer, M. H.
Right arrow Articles by Kupiec-Weglinski, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammer, M. H.
Right arrow Articles by Kupiec-Weglinski, J. W.
The Journal of Immunology, 2001, 166: 596-601.
Copyright © 2001 by The American Association of Immunologists

Homing of In Vitro-Generated Donor Antigen-Reactive CD4+ T Lymphocytes to Renal Allografts Is {alpha}4{beta}1 But Not {alpha}L{beta}2 Integrin Dependent1

Markus H. Hammer*,{dagger}, Yuan Zhai*, Masamichi Katori*, Thomas Ritter{dagger}, Hans-Dieter Volk{dagger}, Ana J. Coito2,* and Jerzy W. Kupiec-Weglinski2,3,*

* Dumont-University of California, Los Angeles Transplant Center, Department of Surgery, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095; and {dagger} Institute of Medical Immunology, Charité, Humboldt-University, Berlin, Germany

The extravasation and sequestration of Ag-reactive T lymphocytes into vascularized organ allografts depend on a cascade of complex interactions among circulating lymphocytes, endothelial cells, and extracellular matrix proteins. Ag-activated donor-specific CD4 T cells are major initiators and effectors in the allograft rejection response. Interfering with the intragraft homing of activated CD4 T cells may represent a novel therapeutic approach in transplant recipients. We have developed a FACS-based short-term homing assay that allows tracing in vitro-generated Ag-reactive CD4 T cells after adoptive transfer in test rat recipients. Allospecific cell lines were preincubated with anti-{alpha}4{beta}1 or anti-{alpha}L{beta}2 mAb, because of enhanced expression of both integrin receptors after alloactivation. The pretreated LewisBN lymphocytes were carboxyfluorescein diacetate succinimidyl ester labeled and adoptively transferred into Lewis rat recipients of Brown Norway kidney allografts. The injection of equal numbers of PKH-26-labeled untreated cells allowed quantitative comparison of both populations in the same animal. Ex vivo treatment with anti-{alpha}4{beta}1 mAb diminished intragraft infiltration of adoptively transferred T cells by 85% in a donor-specific fashion. In contrast, treatment with anti-{alpha}L{beta}2 mAb did not affect intragraft cell sequestration. Hence, blocking {alpha}4{beta}1 integrin interactions represents a novel strategy in preventing local intragraft recruitment of Ag-reactive CD4 T cells in transplant recipients.




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
Z. Hmama, K. Sendide, A. Talal, R. Garcia, K. Dobos, and N. E. Reiner
Quantitative analysis of phagolysosome fusion in intact cells: inhibition by mycobacterial lipoarabinomannan and rescue by an 1{alpha},25-dihydroxyvitamin D3-phosphoinositide 3-kinase pathway
J. Cell Sci., April 15, 2004; 117(10): 2131 - 2140.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. H. Hammer, G. Schroder, K. Risch, A. Flugel, H.-D. Volk, M. Lehmann, and T. Ritter
Antigen-Dependent Transgene Expression in Kidney Transplantation: A Novel Approach Using Gene-Engineered T Lymphocytes
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 511 - 518.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.